Publication Cover
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Revue canadienne des soins respiratoires et critiques et de la médecine du sommeil
Volume 5, 2021 - Issue 2: 2020 Year in Review
686
Views
0
CrossRef citations to date
0
Altmetric
Articles

Asthma

&

References

  • Yang CL, Hicks EA, Mitchell P, et al. 2021 Canadian Thoracic Society Guideline – A Focused Update on the Management of Very Mild and Mild Asthma. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2021; In press. doi:10.1080/24745332.2021.1877043.
  • Cloutier MM, Baptist AP, Blake KV, Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi:10.1016/j.jaci.2020.10.003.
  • Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019.
  • FitzGerald J, Lemiere C, Lougheed M, et al. Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2017;1(4):199–221. doi:10.1080/24745332.2017.1395250.
  • de Jong CCM, Pedersen ESL, Mozun R, et al. Diagnosis of asthma in children: findings from the Swiss Paediatric Airway Cohort. Eur Respir J. 2020;56(5):2000132. doi:10.1183/13993003.00132-2020.
  • Yaghoubi M, Adibi A, Zafari Z, et al. Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. J Allergy Clin Immunol. 2020;145(5):1367–1377.e4. doi:10.1016/j.jaci.2019.11.038.
  • Cabrera CS, Nan C, Lindarck N, Beekman MJHI, Arnetorp S, van der Valk RJP. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β. Eur Respir J. 2020;55(2):1901858. doi:10.1183/13993003.01858-2019.
  • Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β. Eur Respir J. 2020;55(4):1901872. In eng. doi:10.1183/13993003.01872-2019.
  • Peters MC, Mauger D, Ross KR, et al. Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency. Am J Respir Crit Care Med. 2020;202(7):973–982. doi:10.1164/rccm.201909-1813OC.
  • Litonjua AA, Carey VJ, Laranjo N, et al. Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. N Engl J Med. 2020;382(6):525–533. doi:10.1056/NEJMoa1906137.
  • Depner M, Taft DH, Kirjavainen PV, PASTURE study group, et al. Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma. Nat Med. 2020;26(11):1766–1775. doi:10.1038/s41591-020-1095-x.
  • Maestre-Batlle D, Huff RD, Schwartz C, et al. Dibutyl Phthalate Augments Allergen-induced Lung Function Decline and Alters Human Airway Immunology. A Randomized Crossover Study. Am J Respir Crit Care Med. 2020;202(5):672–680. doi:10.1164/rccm.201911-2153OC.
  • Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi:10.1016/S2213-2600(20)30190-9.
  • Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1.
  • Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi:10.1016/S0140-6736(19)32215-9.
  • Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2021;9(1):43–56. doi:10.1016/S2213-2600(20)30412-4.
  • Beurnier A, Jutant EM, Jevnikar M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur Respir J. 2020;56(5):2001875. doi:10.1183/13993003.01875-2020.
  • Lovinsky-Desir S, Deshpande DR, De A, et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol. 2020;146(5):1027–1034.e4. In eng). doi:10.1016/j.jaci.2020.07.026.
  • Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;146(2):327–329.e4. doi:10.1016/j.jaci.2020.06.001.
  • Eddy RL, Svenningsen S, Kirby M, et al. Is Computed Tomography Airway Count Related to Asthma Severity and Airway Structure and Function? Am J Respir Crit Care Med. 2020;201(8):923–933. In eng). doi:10.1164/rccm.201908-1552OC.
  • Mummy DG, Carey KJ, Evans MD, et al. Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency. J Allergy Clin Immunol. 2020;146(4):831–839.e6. doi:10.1016/j.jaci.2020.02.029.
  • Zounemat Kermani N, Saqi M, Agapow P, U-BIOPRED Project Team, et al. Type 2-low asthma phenotypes by integration of sputum transcriptomics and serum proteomics. Allergy. 2021;76(1):380–383. doi:10.1111/all.14573.
  • Smith BM, Zhao N, Olivenstein R, Lemiere C, Hamid Q, Martin JG. Asthma and fixed airflow obstruction: Long-term trajectories suggest distinct endotypes. Clin Exp Allergy. 2021;51(1):39–48. doi:10.1111/cea.13714.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.